Особенности фармакотерапии статинами пациентов пожилого возраста высокого и очень высокого риска

Особенности фармакотерапии статинами пациентов пожилого возраста высокого и очень высокого риска

Автор: Симерзин Василий Васильевич, Фатенков Олег Вениаминович, Низаметдинова Динара Рустамовнабулгакова Светлана Викторовна, Галкина Мария Анатольевна, Панишева Яна Анатольевна, Гаглоев Антон Вячеславович, Серпионова Екатерина Константиновна, Сытдыков Ильнар Халитович, Попова Яна Олеговна

Журнал: Вестник медицинского института "РЕАВИЗ": реабилитация, врач и здоровье @vestnik-reaviz

Рубрика: Клиническая медицина

Статья в выпуске: 1 (43), 2020 года.

Бесплатный доступ

В обзорной статье представлены данные о профилактике сердечно-сосудистых заболеваний и их осложнений у лиц пожилого возраста. В её основе лежит диагностика заболевания, верификация диагноза и риск-стратификация больных. Исходя из этого, у пациентов высокого и очень высокого риска для достижения и контроля целевого уровня холестерина липопротеидов низкой плотности проводится агрессивная липидкоррегирующая фармакотерапия статинами, которая у лиц пожилого возраста имеет свои особенности.

Профилактика, пожилой возраст, фармакотерапия статинами, риск-стратификация, скрининг

Короткий адрес: https://sciup.org/143172310

IDR: 143172310

Список литературы Особенности фармакотерапии статинами пациентов пожилого возраста высокого и очень высокого риска

  • Rosengren A. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? Eur Heart J 2012;33:562-563.
  • Does Higb-Intensity Pitavastatin Therapy Furtber Imptove Clinical Outcomes? The REAL-CAD Study in 13,054 Patients with Stable Coronary Artery Disease, Latr Breaking Clinical Trial Session, American Heart Association (AHA) Annual Scienti fic Session 2917, November 13,2017
  • 2016 ESC/EAS Guidelines for the Management of Dyslipidemias, European Heart Journal, Volume 37, Issue 39 14 October 2016, Pages 2999-3058.
  • Randomized Evalution of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease (REALT-CAD). Clinical Trial.gov,bttps:clinicaltrials.govct2/sbow/NCT01042730.
  • Leticia Fernández-Friera et al. JACC 2017;70:2979-2991.
  • Prospective Studies Collaboration Lewington S Whitlock G Clarke R Sherliker P Emberson J Halsey J Qizilibash N Peto R Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007;370:1829-1839.
  • Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-1503.
  • Ezhov M.V., Sergienko I.V., Aronov D.M. i dr. Diagnostika i korrekciya narushenij lipidnogo obmena s ce-l'yu profilaktiki i lecheniya ateroskleroza // Rossijskie rekomendacii VI peresmotr. Ateroskleroz i dislipidemi. - 2017. - № 28 (3). - S. 5-23.
  • Kazi D.S., Penko J.M., Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease: Review of Evidence and Recommendations for Clinical Practice. Med Clin North Am. 2017;101(4):689-99.
  • Rosenson R.S., Baker S.K., Jacobson T.A., Kopecky S.L., Parker B.A. The National Lipid Association s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol 2014;8:S58-S71.
  • Bojcov S.A., Pogosova N.V., Bubnova M.G. i dr. Kardiovaskulyarnaya profilaktika 2017 // Rossijskie nacional'nye rekomendacii. Rossijskij kardiologicheskij zhurnal. - 2018. № 23 (S6). - S. 7-122.
  • Piepoli M.F., Hoes A.W., Agewall S. et al. ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR) Eur. Heart J. 2016;37(29):2315-81.
  • Brugts J.J., Yetgin T., Hoeks S.E. et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376.
  • Cholesterol Treatment Trialists' (CTT) Collaboration Baigent C Blackwell L Emberson J Holland LE Reith C Bhala N Peto R Barnes EH Keech A Simes J Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-1681.
  • Cholesterol Treatment Trialists' (CTT) Collaboration Fulcher J. O'Connell R. Voysey M. Emberson J. Blackwell L. Mihaylova B. Simes J. Collins R. Kirby A. Colhoun H. Braunwald E. La Rosa J. Pedersen T.R. Tonkin A. Davis B. Sleight P. Franzosi MG Baigent C. Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-1405.
  • 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: lipid modification to reduce cardiovascular risk. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). European Heart Journal 2019;00:1-78.
  • DOI: 10.1093/eurheartj/ehz455
  • Lloyd-Jones D.M., Leip E.P., Larson M.G. et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-798.
  • Berry J.D., Dyer A., Cai X. et al. Lifetime risks of cardiovascular disease. N Engl J Med 2012;366:321-329.
  • Giang K.W., Björck L., Novak M. et al. Stroke and coronary heart disease: predictive power of standard risk factors into old age-long-term cumulative risk study among men in Gothenburg, Sweden. Eur Heart J 2013;34:1068-1074.
  • Wilhelmsen L, Svärdsudd K, Eriksson H et al. Factors associated with reaching 90 years of age: a study of men born in 1913 in Gothenburg, Sweden. J Intern Med 2011;269:441-451.
  • Reiner Z. Primary prevention of cardiovascular disease with statins in the elderly. Curr Atheroscler Rep 2014;16:420.
  • Savarese G., Gotto A.M., Jr. Paolillo S. et al. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. J. Am Coll Cardiol 2013;62:2090-2099.
  • Downs J.R., Clearfield M., Weis S. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
  • Glynn R.J., Koenig W., Nordestgaard B.G. et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med 2010;152:488-496, W174.
  • Cardiovascular disease: risk assessment and reduction, including lipid modification. NICE guidelines [CG181] Published date: July 2014 Last updated: July 2016. https://www.nice.org.uk/guidance/cg181/chapter/1-Recommendations#lipid-modification-therapy-for-the-primary-and-secondary-prevention-of-cvd-2
  • Hunt D, Young P, Simes J et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001;134:931-940.
  • Gränsbo K, Melander O, Wallentin L et al. Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment. J Am Coll Cardiol 2010;55:1362-1369.
  • Goblirsch G, Bershow S, Cummings K et al. Stable coronary artery disease. Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 May. 71 p. https://www.icsi. org/_asset/t6bh6a/scad.pdf.
  • Writing Committee, Lloyd-Jones D.M., Morris P.B. et al. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDC-cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol.2016;68(1):92-125.
  • DOI: 10.1016/j.jacc.2016.03.519
  • Landmesser U, John Chapman M, Farnier M et al.; European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. European Heart Journal (2016) Oct 27
  • DOI: 10.1093/eurheartj/ehw480
  • Fihn S.D., Gardin J.M., Abrams J. et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012;60 (24):e44-e164.
  • Miettinen T.A., Pyörälä K., Olsson A.G. et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997;96:4211-4218.
  • Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
  • Hunt D Young P Simes J Hague W Mann S Owensby D Lane G Tonkin A. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001;134:931-940.
  • Lewis S.J., Moye L.A., Sacks F.M. et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 1998;129:681-689.
  • Wenger N.K., Lewis S.J., Herrington D.M., Bittner V., Welty F.K. Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med 2007;147:1-9.
  • Shepherd J., Blauw G.J., Murphy M.B. et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-1630.
  • Deedwania P., Stone P.H., Bairey Merz C.N. et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007;115:700-707.
  • Stable angina: management. NICE Clinical guideline [CG126] Last updated: August 2016 https://www.nice.org.uk/guidance/cg126/chapter/1-Guidance#anti-anginal-drug-treatment.
Еще
Статья научная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp